Dihexa for Cognitive Enhancement

Evidence Review created on 04/24/2026 using AI4L / Opus 4.7

Also known as: PNB-0408, N-Hexanoic-Tyr-Ile-(6) Aminohexanoic Amide, Dihexa Acetate

Motivation

Dihexa is a synthetic peptide derived from angiotensin IV, originally developed at Washington State University as a candidate treatment for neurodegenerative diseases. It has attracted unusually strong interest in cognitive enhancement circles because preclinical work reported that it promotes new synaptic connections at a potency many orders of magnitude beyond the brain’s own growth factors, while remaining orally active and able to cross the blood-brain barrier. These combined properties are rare among peptides and have made dihexa a compound of interest to both drug development and the nootropic community.

Its commercial trajectory passed through Athira Pharma, which developed a related injectable prodrug (fosgonimeton) for dementia and pursued that program through clinical trials. The trajectory of the research program and the status of the foundational mechanism work have come under scrutiny, and community self-experimentation with dihexa has continued in parallel, with the compound remaining obtainable through peptide and compounding channels whose regulatory status is under active review.

This review examines what the preclinical evidence can and cannot support for dihexa as a cognitive enhancement tool, its proposed mechanisms, the regulatory and sourcing situation, and the safety uncertainties that the absence of human clinical data leaves unresolved.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Dihexa

The Grokipedia entry provides a detailed overview of dihexa as a synthetic oligopeptide analog of angiotensin IV, covering its chemical structure, its mechanism through hepatocyte growth factor/c-Met receptor potentiation, the preclinical procognitive evidence in Alzheimer’s and Parkinson’s disease models, its unusually long half-life, and its relationship to the clinical-stage prodrug fosgonimeton.

Examine

No dedicated Examine article for dihexa was found. Dihexa is an experimental research peptide with no human clinical trials, which is consistent with Examine’s focus on supplements and interventions with established human evidence; Examine does not typically cover experimental research peptides of this class.

ConsumerLab

No dedicated ConsumerLab article for dihexa was found. ConsumerLab does not typically cover experimental research peptides, which is consistent with its product-testing focus on commercially available dietary supplements.

Systematic Reviews

This section lists the systematic review literature evaluating the cognitive effects of angiotensin IV and its analogs, including dihexa.

Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies - Ho & Nation, 2018

A systematic review of 32 experimental (non-human) studies examining the cognitive effects of angiotensin IV and angiotensin-(1-7), in which eight of the nine studies testing angiotensin IV and its analogs (including dihexa) in cognitive-deficit models reported improvements in spatial working memory and passive avoidance tasks. The review noted that all evidence is preclinical and that brain renin-angiotensin system peptides appear most effective when administered near the time of learning acquisition or retention.

No additional systematic reviews or meta-analyses specifically evaluating dihexa for cognitive enhancement were found on PubMed as of 04/24/2026. The Ho & Nation, 2018 review remains the only systematic assessment, and it is restricted to animal studies.

Mechanism of Action

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic oligopeptide derived from angiotensin IV (AngIV), a fragment of the angiotensin system identified in the 1990s as having procognitive properties in animals. The compound was designed by chemically modifying the tripeptide core Nle-Tyr-Ile to improve metabolic stability, oral bioavailability, and blood-brain barrier penetration.

HGF/c-Met pathway activation: Dihexa has been reported to bind with high affinity (picomolar range) to HGF (hepatocyte growth factor, a protein that promotes cell growth, survival, and tissue repair) and to potentiate its signaling through the c-Met receptor, driving synaptogenesis (formation of new synaptic connections), spinogenesis (growth of dendritic spines), and neuronal survival. The 2014 Benoist et al. paper that established this mechanism was retracted in April 2025 after Washington State University confirmed image falsification in its figures; the mechanism itself continues to be investigated but now rests on work conducted by parties other than the original commercial developers
PI3K/AKT signaling: A 2021 study by Sun et al. in APP/PS1 transgenic mice (a genetic mouse model of Alzheimer’s disease) reported that dihexa activated the PI3K/AKT (phosphoinositide 3-kinase/protein kinase B, a signaling pathway involved in cell survival and growth) pathway, reduced astrocyte and microglial activation, decreased the pro-inflammatory cytokines IL-1β (interleukin-1 beta, a protein that promotes inflammation) and TNF-α (tumor necrosis factor alpha, a pro-inflammatory signaling molecule), and increased the anti-inflammatory cytokine IL-10 (interleukin-10, an anti-inflammatory signaling molecule). A PI3K inhibitor reversed these effects, supporting pathway engagement
Synaptogenesis in vitro: In hippocampal cell cultures, dihexa was reported to promote new synaptic connections at picomolar concentrations, with potency described as approximately 10 million times greater than BDNF (brain-derived neurotrophic factor, the brain’s primary growth factor for neuronal health and synaptic plasticity) in bench assays. This potency claim derives from in vitro assays from the original developer’s laboratory and has not been independently replicated in vivo or in human systems

Key pharmacological properties:

Half-life: Approximately 12.7 days in rats following intravenous administration, with a shorter initial distribution phase; this is an unusually long duration for a peptide. Human half-life data are not available. If similar kinetics apply to humans, steady-state concentrations would build over several weeks of daily dosing
Oral bioavailability: Unlike most peptides, dihexa survives gastrointestinal digestion and is orally active, an effect attributed to its N-hexanoyl and C-terminal aminohexanoic acid modifications, which increase hydrophobicity and resist enzymatic degradation
Blood-brain barrier penetration: The lipophilic modifications allow dihexa to cross the blood-brain barrier, with radiolabeled studies showing preferential accumulation in hippocampus and cortex
Metabolism: Dihexa shows minimal phase I metabolism and resists peptidase activity, with clearance proceeding through hepatic and renal routes at a low overall rate. Specific CYP (cytochrome P450, a family of liver enzymes responsible for metabolizing most drugs) involvement has not been characterized. Fosgonimeton (ATH-1017), a phosphate prodrug of a related active metabolite, was developed to improve pharmacokinetic properties for clinical use

Historical Context & Evolution

Dihexa emerged from research at Washington State University by Drs. Joseph Harding and John Wright beginning in the early 1990s. Their work focused on the brain renin-angiotensin system, specifically the observation that angiotensin IV enhanced cognitive performance in animal models when delivered centrally. Angiotensin IV itself was metabolically unstable, could not cross the blood-brain barrier, and required direct brain injection.

Over two decades, the team systematically modified the angiotensin IV molecule to improve stability and bioavailability. They identified that the procognitive activity resided in the three N-terminal amino acids (Nle-Tyr-Ile) and then added chemical modifications to increase hydrophobicity and metabolic resistance. The resulting compound, dihexa, was first described in detail in a 2013 publication by McCoy, Benoist, Wright, and Harding in the Journal of Pharmacology and Experimental Therapeutics.

A pivotal 2014 paper by Benoist et al. in the same journal proposed that dihexa’s procognitive effects were mediated through the hepatocyte growth factor/c-Met receptor system rather than the previously hypothesized AT4 receptor. This mechanistic finding was commercially significant: Leen Kawas, a doctoral student in Harding’s laboratory and co-author of the paper, co-founded M3 Biotechnology (later renamed Athira Pharma) to develop a clinical-stage version of the compound. Athira advanced fosgonimeton, a phosphate prodrug delivering a related active metabolite, into human clinical trials for Alzheimer’s disease.

In June 2021, allegations emerged on PubPeer that western blot images in several papers co-authored by Kawas during her doctoral work had been manipulated. Washington State University conducted a research integrity investigation and found that Kawas and Harding were responsible for falsified and fabricated data in the Benoist et al. 2014 figures. Kawas resigned from Athira in October 2021. The paper received an expression of concern and was formally retracted in April 2025. In January 2025, Athira agreed to pay over $4 million to settle False Claims Act allegations relating to NIH grants that referenced the compromised research.

Despite the retraction, Athira’s clinical program in fosgonimeton continued and then failed: the Phase 2/3 LIFT-AD trial did not meet its primary endpoint in mild-to-moderate Alzheimer’s disease, the Phase 2 SHAPE trial in Parkinson’s disease dementia and dementia with Lewy bodies was terminated, and the company announced a transition to a new name (LeonaBio) and shifted focus to other programs. Dihexa itself has never been tested in a human clinical trial and has never been approved by any regulatory agency for any indication.

Its regulatory status in the compounding channel has been in flux. Dihexa acetate was nominated for the FDA’s 503A bulks list (the list of bulk drug substances allowed for compounding by 503A pharmacies) but has not been added; the FDA announced plans to convene the Pharmacy Compounding Advisory Committee to review dihexa acetate and several other peptides before the end of February 2027, which would be followed by formal rulemaking.

Expected Benefits

A dedicated search for dihexa’s benefit profile was performed using PubMed, web search, and expert sources. All available evidence is preclinical; no human clinical trial of dihexa itself has been conducted, and the closest human data come from the related injectable prodrug fosgonimeton, which failed its pivotal trial in Alzheimer’s disease.

Low 🟩

Procognitive Effects in Dementia Models

In rodent models of cognitive impairment, dihexa has reversed scopolamine-induced memory deficits and improved spatial learning in aged rats in the Morris water maze at oral doses around 2 mg/kg. A 2021 study in APP/PS1 mice by Sun et al. reported that dihexa restored spatial learning, increased neuronal density and synaptophysin (a presynaptic marker protein) expression, and reduced neuroinflammation through PI3K/AKT pathway activation. These effects have been reported by more than one laboratory. However, all controlled data are from animal models, the key HGF/c-Met mechanism paper was retracted, and the related clinical-stage prodrug fosgonimeton failed its Phase 2/3 trial in human Alzheimer’s disease.

Magnitude: In aged rat Morris water maze experiments, oral dihexa at 2 mg/kg restored performance to a level comparable to young control animals; translation to human cognitive enhancement is unknown.

Synaptogenesis Promotion

Dihexa has been reported to promote new synaptic connections in hippocampal cultures at picomolar concentrations, with potency described as roughly 10 million times greater than BDNF in bench synaptogenesis assays. This effect was proposed to operate through HGF/c-Met receptor potentiation, though the primary mechanism paper was retracted due to data falsification. Independent support for synaptogenic activity comes from the PI3K/AKT APP/PS1 study, which showed increased synaptophysin expression and restored neuronal density, but the specific magnitude claim relative to BDNF derives from the compromised research.

Magnitude: Not quantified in available studies.

Neuroprotective Effects

Dihexa has shown neuroprotective properties in several preclinical models, including reductions in astrocyte and microglial activation and in pro-inflammatory cytokines in the APP/PS1 PI3K/AKT study, along with earlier reports from the original developers of motor-restorative effects in Parkinson’s disease animal models. However, a 2024 study by Wells et al. found that dihexa did not protect rats from 3-nitropropionic acid-induced Huntington’s disease-like symptoms, indicating that neuroprotective effects are not universal across neurodegenerative models. Taken together, the neuroprotective signal is model-dependent and has not been validated in humans.

Magnitude: Not quantified in available studies.

Speculative 🟨

Cognitive Enhancement in Healthy Individuals

The use of dihexa for cognitive enhancement in healthy, non-impaired individuals is entirely speculative. All preclinical data involve models of cognitive deficit (scopolamine-induced impairment, aged rats, transgenic Alzheimer’s mice), not enhancement above a normal baseline. Community reports of improved focus, memory, and mental clarity are anecdotal and uncontrolled. Whether promoting additional synaptogenesis in a healthy brain translates into functional cognitive improvement, or instead interferes with established circuits, is unknown.

Restoration of cognitive performance in aged rat models has been read as suggestive of a role in counteracting age-related synaptic loss and early cognitive decline in humans. No studies have examined long-term outcomes, human biomarker effects, or downstream changes in disease trajectory, and the extended activation of a growth-promoting pathway raises counterbalancing concerns about oncogenic risk that become more relevant with longer use.

Benefit-Modifying Factors

Baseline cognitive status: All demonstrated benefits of dihexa are in models of cognitive impairment. Individuals with pre-existing cognitive deficits may theoretically experience greater benefit than cognitively healthy individuals, though this has not been tested in humans
Age: Aged animal models show the most robust response to dihexa, suggesting that age-related synaptic loss may create a larger window for synaptogenic benefit. Older adults may therefore be the most relevant target population, though they also carry higher theoretical cancer risk from prolonged growth factor pathway activation
Genetic polymorphisms: No pharmacogenomic data exist for dihexa in humans. Variants in the MET gene (which encodes the c-Met receptor) or in HGF expression could theoretically modify response, but this is entirely speculative
Baseline biomarker levels: No validated biomarkers exist for predicting dihexa response. Individuals with lower baseline BDNF levels or reduced synaptic density might theoretically have a greater window for synaptogenic benefit, but no data support this hypothesis
Sex-based differences: No sex-stratified efficacy data exist for dihexa. Most preclinical studies used male rodents exclusively
Pre-existing health conditions: Individuals with any history of cancer or pre-cancerous conditions face potentially elevated risk from chronic HGF/c-Met pathway activation, which could meaningfully shift the net benefit calculation. Individuals with active neurodegenerative disease may have a different risk-benefit profile than healthy individuals seeking enhancement

Potential Risks & Side Effects

A dedicated search for dihexa’s side effect and risk profile was performed using PubMed, drug reference sources, the Alzheimer’s Drug Discovery Foundation report, and practitioner and community reports. No formal human safety data exist for dihexa; the risk profile is derived from preclinical data, mechanistic extrapolation, limited data on the related prodrug fosgonimeton, and uncontrolled community reports.

Medium 🟥 🟥

Theoretical Cancer Risk via HGF/c-Met Pathway Activation ⚠️ Conflicted

The HGF/c-Met signaling axis is one of the most extensively studied oncogenic pathways in cancer biology, driving cell proliferation, tissue invasion, metastasis, angiogenesis (formation of new blood vessels), and resistance to apoptosis (programmed cell death) — and is itself the target of multiple approved cancer drugs. By potentiating this same pathway, chronic dihexa exposure raises a theoretical tumorigenic concern that the Alzheimer’s Drug Discovery Foundation has explicitly flagged. Short-term animal studies reported no neoplastic induction, but they were not designed or powered to detect carcinogenesis, and no long-term data exist. The conflict is that the mechanism proposed to produce cognitive benefit is the same one implicated in tumor promotion, and no data resolve whether chronic low-dose activation in humans translates into meaningful oncologic risk.

Magnitude: Not quantified in available studies.

Absence of Human Safety Data

Dihexa itself has never been administered to humans in a controlled clinical trial. All safety inferences are extrapolated from animal studies, from the prodrug fosgonimeton’s clinical program, or from uncontrolled community self-experimentation. Fosgonimeton was well tolerated in a Phase 1 trial in 88 subjects at doses up to 90 mg subcutaneously over 9 days, with no drug-related serious adverse events reported. However, fosgonimeton is a subcutaneously administered prodrug with different pharmacokinetic properties than oral dihexa, and a 9-day exposure cannot address long-term safety or cumulative-exposure effects.

Magnitude: Not quantified in available studies.

Low 🟥

Overstimulation of Synaptogenesis

Dihexa’s proposed mechanism of promoting new synaptic connections raises the concern that excessive or inappropriately directed synaptogenesis could produce maladaptive neural wiring rather than functional improvement. The brain normally prunes unnecessary synapses as part of healthy circuit refinement. Chronically stimulating synapse formation in the absence of appropriate activity-dependent selection could in principle disrupt established networks, particularly in healthy brains where synaptic density is already optimized. This concern is mechanistic and has not been tested in humans.

Magnitude: Not quantified in available studies.

Reported Mild Side Effects (Anecdotal)

Community self-experimentation reports describe mild headaches, insomnia (particularly with evening dosing), restlessness, mental overstimulation, occasional nausea, changes in taste, and mood fluctuations. These reports are uncontrolled and subject to significant placebo and nocebo effects. Their frequency and severity cannot be reliably estimated from anecdotal data.

Magnitude: Not quantified in available studies.

Peripheral HGF/c-Met Effects

HGF/c-Met signaling is not limited to the central nervous system. The pathway operates in liver, kidney, lung, and other tissues, where it contributes to tissue repair, fibrosis, and cellular proliferation. Systemic exposure to dihexa could in principle potentiate HGF/c-Met signaling in peripheral organs, with unknown consequences for organ function, wound healing dynamics, or fibrotic processes over extended use.

Magnitude: Not quantified in available studies.

Speculative 🟨

Long-Term Neurological Effects

The exceptionally long half-life of dihexa (approximately 12.7 days in rats) means that chronic daily dosing would lead to substantial accumulation over weeks. The long-term neurological consequences of sustained HGF/c-Met potentiation in the brain are unknown. Potential concerns include altered synaptic plasticity regulation, disruption of normal memory consolidation and pruning, and unknown effects on brain regions beyond the hippocampus.

Interaction with Undetected Pre-Cancerous Conditions

Because HGF/c-Met pathway activation promotes angiogenesis and cell proliferation, there is a speculative concern that dihexa could accelerate the growth of undetected pre-cancerous or cancerous lesions. The long half-life amplifies this concern by making effects difficult to reverse quickly after administration stops.

Risk-Modifying Factors

Genetic polymorphisms: No pharmacogenomic data exist for dihexa. Polymorphisms in the MET gene (which encodes the c-Met receptor) or in HGF expression could theoretically alter sensitivity to dihexa’s growth factor potentiation, potentially modifying both efficacy and oncogenic risk, but this remains entirely speculative
Cancer history or predisposition: Individuals with any personal or family history of cancer, particularly cancers known to involve HGF/c-Met dysregulation (including glioblastoma, hepatocellular carcinoma, non-small cell lung cancer, renal cell carcinoma, and gastric cancer), face potentially amplified risk from chronic c-Met pathway potentiation
Baseline biomarker levels: Elevated baseline HGF levels or high c-Met expression could theoretically increase sensitivity to dihexa’s effects in both target and non-target tissues. No practical biomarker testing for this purpose currently exists
Sex-based differences: No sex-specific risk data exist for dihexa. Certain cancers with HGF/c-Met involvement (e.g., breast cancer, ovarian cancer) have sex-specific prevalence that could create differential risk profiles
Pre-existing health conditions: Liver or kidney disease may alter dihexa’s clearance. Individuals with conditions involving aberrant tissue growth or fibrosis may face elevated risk from additional growth factor pathway stimulation
Age-related considerations: Older adults have a higher baseline incidence of occult malignancy and pre-cancerous lesions, which could amplify the theoretical risk from chronic growth factor pathway activation. Conversely, age-related synaptic loss may create the largest window for potential cognitive benefit, producing a complex risk-benefit profile at the older end of the target range

Key Interactions & Contraindications

Dihexa’s interaction profile is poorly characterized given the absence of human pharmacokinetic studies and formal drug-interaction assessments. The interactions below are derived from mechanistic reasoning and from the known properties of the HGF/c-Met pathway.

c-Met inhibitors (crizotinib, cabozantinib, capmatinib, tepotinib): Absolute contraindication. These oncology drugs are prescribed to block c-Met signaling; co-administration with dihexa would create direct pharmacological antagonism. Clinical consequence: potential treatment failure for the underlying malignancy
HGF pathway–targeting agents: Absolute contraindication. Any therapeutic intended to modulate hepatocyte growth factor signaling, including investigational anti-HGF antibodies and bispecific antibodies targeting c-Met, would potentially interact with dihexa. Clinical consequence: unpredictable modification of oncologic therapy
Immunosuppressants (cyclosporine, tacrolimus, sirolimus): Caution. HGF/c-Met activation has immunomodulatory effects, and chronic growth factor stimulation in immunocompromised patients may alter the balance between tissue repair and immune surveillance. Clinical consequence: altered immune regulation; mitigation: physician oversight and monitoring
Other growth factor therapies (growth hormone, IGF-1 (insulin-like growth factor 1, a hormone that promotes cell growth and proliferation)): Caution. Combining multiple growth-promoting agents could theoretically amplify oncogenic risk through additive or synergistic pathway activation. Clinical consequence: theoretically elevated cancer risk
Anticoagulants (warfarin, heparin, direct oral anticoagulants (drugs such as apixaban and rivaroxaban that inhibit specific clotting factors)): Monitor. HGF promotes angiogenesis and can influence vascular remodeling; interaction with anticoagulants is speculative but represents a theoretical concern for altered bleeding or vascular risk. Clinical consequence: uncertain
Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs) (ibuprofen, naproxen, aspirin): Monitor. No direct pharmacokinetic interaction is established, but combined effects on platelet function, gastrointestinal integrity, and tissue remodeling via HGF/c-Met potentiation are uncharacterized. Clinical consequence: uncertain
Nootropic and neurotrophic supplements (lion’s mane, alpha-GPC, phosphatidylserine): Monitor. Supplements that promote nerve growth factor production or cholinergic signaling could theoretically add to dihexa’s synaptogenic mechanism. No interaction data exist. Clinical consequence: uncertain additive neurotrophic effects

Populations who should avoid dihexa:

Individuals with any active malignancy or history of cancer, particularly HGF/c-Met–associated cancers (glioblastoma, hepatocellular carcinoma, non-small cell lung cancer, renal cell carcinoma, gastric cancer)
Individuals undergoing cancer treatment of any type
Pregnant or breastfeeding individuals (no reproductive toxicity data exist)
Individuals under 25 years of age (brain development is ongoing and the effects of exogenous synaptogenesis promotion are unknown)
Individuals with moderate-to-severe hepatic impairment (Child-Pugh Class B or C; clearance and accumulation profiles are unknown)

Risk Mitigation Strategies

Comprehensive cancer screening before initiation: Given the theoretical risk of promoting occult malignancy through chronic HGF/c-Met activation, a thorough cancer screen (age-appropriate screenings, a baseline tumor marker panel, and imaging as clinically indicated) before starting dihexa mitigates the risk of accelerating undetected pre-cancerous or cancerous lesions
Limited duration of use with defined endpoints: Using dihexa in defined short courses (e.g., 4–8 weeks) rather than indefinitely limits cumulative exposure and reduces the theoretical risk that prolonged growth factor pathway activation could contribute to neoplastic changes. The long half-life (approximately 12.7 days in rats) means that even short courses produce weeks of residual exposure after the last dose
Lowest effective dose approach: Starting at the lowest available dose (e.g., 2–5 mg daily) and titrating only if tolerated reduces the risk of excessive synaptogenesis, peripheral HGF/c-Met effects, and accumulation-related adverse events; given dihexa’s reported potency, even small dose differences may produce substantially different biological effects
Regular oncologic surveillance during use: Periodic cancer screening at minimum every 6–12 months during use mitigates the risk of undetected malignancy by enabling early detection of any growth-promoting effects of chronic c-Met potentiation
Avoidance of concurrent growth-promoting agents: Not combining dihexa with growth hormone, IGF-1, or other growth-factor therapies reduces the theoretical risk of additive or synergistic oncogenic pathway activation
Morning-only dosing to protect sleep: Dosing dihexa in the morning (rather than evening or split across the day) mitigates the anecdotally reported risk of insomnia and the indirect cognitive cost of sleep disruption

Therapeutic Protocol

No standardized human therapeutic protocol exists for dihexa. The compound has never been evaluated in a human clinical trial, and all dosing information derives from animal studies and uncontrolled community self-experimentation. The following information is compiled from preclinical research and practitioner reports; it does not constitute a validated protocol.

Preclinical dosing: In animal studies by the Harding and Wright laboratory, oral doses of 2 mg/kg in rats reversed cognitive deficits. Direct translation to human equivalent doses is unreliable owing to species differences in metabolism, bioavailability, and receptor density
Community-reported dosing: Anecdotal reports describe oral or sublingual doses of 5–40 mg daily, with some individuals reporting doses up to 80 mg. The most commonly discussed starting doses are 5–10 mg daily; commercially available capsule strengths include 2 mg, 10 mg, 20 mg, and 25 mg. No specific practitioner or clinic has established a validated human protocol
Administration route: Oral capsules and sublingual preparations are the most commonly reported routes. Topical creams exist, but their rationale for cognitive enhancement is unclear given that systemic exposure after topical application has not been characterized
Timing: No evidence-based timing guidance exists. Anecdotal reports suggest morning dosing to minimize potential insomnia; given the long half-life, single daily dosing is sufficient
Competing therapeutic approaches: Where competing therapeutic approaches exist, the main distinction is between oral dihexa itself and the injectable prodrug fosgonimeton (ATH-1017), developed by Athira Pharma (which was co-founded by Leen Kawas, subsequently found responsible for data falsification in foundational dihexa research). Fosgonimeton was designed for improved pharmacokinetics and entered Phase 2/3 clinical trials for Alzheimer’s disease, where it failed to meet its primary endpoint, leading Athira to pause further development and rename itself LeonaBio.
Half-life considerations: A rat IV half-life of approximately 12.7 days is exceptionally long. If this translates similarly to humans, daily dosing would produce substantial accumulation, and effects would persist for weeks after discontinuation — making rapid dose adjustment impractical
Single versus split dosing: Given the extremely long half-life, there is no pharmacokinetic rationale for split dosing; once-daily administration is sufficient
Genetic polymorphisms: No pharmacogenomic data exist for dihexa. Polymorphisms affecting HGF expression, c-Met receptor density, or PI3K/AKT pathway activity could theoretically modify response, but no testing is available
Sex-based differences: No sex-stratified data exist. Most animal studies used male subjects exclusively
Age-related considerations: Older adults show the most robust preclinical response but also face higher baseline cancer risk from chronic growth factor activation. No age-adjusted dosing data exist
Baseline biomarker levels: No validated biomarkers exist for predicting dihexa response or monitoring its effects
Pre-existing health conditions: Any history of cancer is a contraindication. Hepatic or renal impairment could alter clearance and accumulation profiles unpredictably

Discontinuation & Cycling

Duration of use: No evidence supports either lifelong or time-limited use. Given the absence of long-term safety data and the theoretical cancer risk, time-limited use with defined endpoints appears more prudent than indefinite administration
Withdrawal effects: No formal data exist on withdrawal effects. Given dihexa’s extremely long half-life, biological effects would taper gradually over weeks after the last dose. Any structural changes to synaptic architecture would not rapidly reverse on discontinuation
Tapering protocol: The long half-life makes a formal taper unnecessary from a pharmacokinetic standpoint. Abrupt discontinuation still produces weeks of declining drug levels
Cycling: Some community protocols suggest cycling patterns (e.g., 4–8 weeks on followed by an equivalent or longer period off) to limit cumulative exposure and allow for cancer surveillance between cycles. No controlled evidence supports or refutes specific cycling protocols

Sourcing and Quality

Regulatory status: Dihexa is not FDA-approved for any indication and is classified as a research compound. It is not a dietary supplement. Its availability through compounding pharmacies is under active regulatory review; the FDA has announced plans to convene the Pharmacy Compounding Advisory Committee to review dihexa acetate for the 503A bulks list before the end of February 2027
Purity and identity verification: Because dihexa is sourced primarily from research chemical suppliers and peptide vendors rather than regulated pharmaceutical manufacturers, product purity, identity, and potency are not guaranteed by standard pharmaceutical oversight. Certificates of analysis (COA) from third-party laboratories verifying peptide identity (by mass spectrometry), purity (by HPLC (high-performance liquid chromatography, a technique used to separate and quantify components in a mixture), target greater than 98%), and absence of endotoxins and heavy metals are essential
Formulation considerations: Dihexa is available as oral capsules, sublingual preparations, and topical creams. The oral route has preclinical support for bioavailability; sublingual administration is used by some practitioners to attempt improved absorption, although no comparative bioavailability data exist in humans
Compounding pharmacies: When available, preparations from 503A or 503B facilities that follow current good manufacturing practices provide greater quality assurance than research-grade suppliers; availability depends on the evolving FDA decision on compounding status
Storage: Dihexa peptide should be stored per manufacturer specifications, typically in a cool, dry environment away from light. Reconstituted or liquid formulations may require refrigeration

Practical Considerations

Time to effect: Community reports suggest subjective cognitive effects may be noticed within days to 1–2 weeks of starting dihexa. Given the long half-life, steady-state concentrations would not be reached for several weeks, and full structural synaptogenic effects, if they occur, would likely require even longer. Expectations of immediate effects should be tempered
Common pitfalls: The most significant pitfall is conflating anecdotal reports of cognitive improvement with demonstrated efficacy. All controlled evidence is from animal models, the key mechanistic paper has been retracted, and the related prodrug failed its pivotal clinical trial in Alzheimer’s disease. A second common mistake is assuming that the extreme in vitro potency claim (10 million times BDNF) translates directly to in vivo effects or therapeutic benefit. Users should also be aware that the long half-life means effects and any adverse reactions persist for weeks after discontinuation
Regulatory status: Dihexa is not approved by the FDA or any other regulatory agency for any medical use and is classified as a research compound. Using it for cognitive enhancement is off-label and unsupervised by regulatory safety monitoring
Cost and accessibility: Dihexa is relatively expensive compared with conventional nootropics, with costs varying markedly between research-grade peptide vendors and compounding pharmacies. Availability may be limited or interrupted depending on regulatory decisions regarding compounding status

Interaction with Foundational Habits

Sleep: Anecdotal reports indicate that dihexa may cause insomnia or restlessness, particularly with later-day dosing. Because sleep is central to memory consolidation, synaptic pruning, and glymphatic (brain waste-clearance) function, any sleep-disrupting effect would be directly counterproductive to the cognitive enhancement goal. Morning dosing is the practical mitigation. Direction: potentially blunting; mechanism: possible catecholaminergic or histaminergic stimulation (not confirmed)
Nutrition: No specific dietary interactions have been identified for dihexa. General nutritional adequacy supporting brain health (omega-3 fatty acids, B vitamins, antioxidants) may support the underlying neural substrate on which dihexa is proposed to act. No foods are known to interfere with or enhance absorption. Direction: none established
Exercise: Aerobic exercise is one of the most robust physiological stimulators of BDNF production and endogenous synaptogenesis. Exercise could theoretically potentiate dihexa’s proposed synaptogenic effects through complementary growth factor stimulation; conversely, combining exogenous and endogenous growth factor stimulation may amplify unknown risks. Direction: potentially potentiating; mechanism: additive neurotrophic signaling through complementary pathways
Stress management: Chronic psychological stress elevates cortisol and suppresses BDNF production and hippocampal neurogenesis. A high-stress environment could theoretically blunt dihexa’s proposed benefits by creating a hostile neural environment for new synapse formation and survival. Stress reduction practices may support the neural conditions under which dihexa’s effects are proposed to occur. Direction: indirect; mechanism: cortisol-mediated suppression of neurotrophic signaling

Monitoring Protocol & Defining Success

Baseline and ongoing monitoring for dihexa use is particularly important given the absence of established safety data and the theoretical risks associated with chronic HGF/c-Met pathway activation.

Baseline testing should include a comprehensive metabolic panel (CMP, a blood test covering electrolytes, glucose, and kidney and liver markers), a complete blood count (CBC, a blood test measuring red cells, white cells, and platelets), and cancer screening appropriate to age and risk profile before initiating dihexa.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
CMP	Within standard ranges	Establishes liver and kidney function baseline for monitoring accumulation	Comprehensive metabolic panel. Fasting; repeat at 4 weeks and every 3–6 months
CBC	Within standard ranges	Detects hematological abnormalities that could indicate bone marrow effects	Complete blood count. Baseline and every 3–6 months
ALT	10–26 U/L	Monitors hepatic function given unknown effects of chronic HGF activation on liver	Alanine aminotransferase. Fasting; part of CMP but highlighted for importance. Conventional: <35–56 U/L
AST	10–26 U/L	Monitors hepatic and general tissue health	Aspartate aminotransferase. Fasting; elevated AST with normal ALT may indicate non-hepatic tissue effects. Conventional: <35–40 U/L
GGT	10–30 U/L	Sensitive marker for hepatic stress and biliary function	Gamma-glutamyl transferase. Not always included in standard CMP; request separately. Conventional: <65 U/L
HGF serum levels	No established optimal range	May indicate the degree of HGF/c-Met system engagement	Research-grade assay; not widely available. Interpret with caution as reference ranges are not established for this context
CEA, AFP, CA 19-9	Within standard ranges	Tumor-marker panel for colorectal, hepatic, and pancreatic malignancy surveillance	Carcinoembryonic antigen, alpha-fetoprotein, cancer antigen 19-9. Baseline and every 6–12 months; elevated results warrant further imaging and evaluation
PSA	<2.0 ng/mL	Prostate cancer surveillance given growth factor activation concerns	Prostate-specific antigen; men only. Men over 40; baseline and annually. Conventional: <4.0 ng/mL

Ongoing monitoring cadence: at 4 weeks, 12 weeks, and then every 3–6 months during use. Annual comprehensive cancer screening is appropriate for the duration of use.

Qualitative markers:

Subjective cognitive performance (memory, focus, mental clarity, problem-solving ability)
Sleep quality and duration (monitoring for insomnia or disruption)
Mood and emotional stability (monitoring for anxiety, restlessness, or mood swings)
Energy levels and mental stamina throughout the day
Any new or unusual physical symptoms (pain, lumps, unexplained weight changes)

Emerging Research

Fosgonimeton (ATH-1017) clinical trial outcomes: The Phase 2/3 LIFT-AD trial (NCT04488419) enrolled 554 participants with mild-to-moderate Alzheimer’s disease and failed to meet its primary endpoint on the Global Statistical Test (a composite of cognition and function) at 26 weeks. The Phase 2 ACT-AD trial (NCT04491006; 77 participants) used ERP P300 latency as its primary endpoint and earlier reported signals of effect on cognitive measures in a smaller subset of patients. The Phase 2 SHAPE trial (NCT04831281; 28 participants enrolled, primary endpoint the Global Statistical Test) in Parkinson’s disease dementia and dementia with Lewy bodies was terminated early. These are the closest approximation to human data for dihexa’s mechanism, although fosgonimeton is an injectable prodrug with different pharmacokinetics than oral dihexa
PI3K/AKT pathway validation: The 2021 study by Sun et al. reporting that dihexa activates PI3K/AKT signaling in APP/PS1 mice provides a mechanistic pathway independent of the retracted HGF/c-Met paper. Whether this pathway mediates cognitive effects in humans or represents a parallel phenomenon remains to be determined
Huntington’s disease model failure: The 2024 study by Wells et al. showed that dihexa (PNB-0408) did not protect rats from 3-nitropropionic acid-induced Huntington’s disease-like symptoms, suggesting that its neuroprotective effects are not universal across neurodegenerative pathways and adding a cautionary data point to the overall preclinical picture
Research integrity resolution: The formal retraction of Benoist et al., 2014 in April 2025 and Athira Pharma’s $4 million False Claims Act settlement in January 2025 represent ongoing resolution of the data integrity issues that have shaped dihexa research. Future mechanistic work will need to establish the compound’s pathway of action independently of the compromised findings
Compounding-pharmacy regulatory review: The FDA has scheduled the Pharmacy Compounding Advisory Committee to review dihexa acetate for the 503A bulks list before the end of February 2027. The outcome will determine whether dihexa can be legally prepared by 503A compounding pharmacies or will effectively remain available only through research chemical channels

Conclusion

Dihexa is a synthetic peptide derived from angiotensin IV that has shown procognitive and neuroprotective effects in animal models, through promotion of new synaptic connections and activation of growth factor signaling in the brain. Its oral bioavailability and blood-brain barrier penetration distinguish it from most peptide compounds, and its reported in vitro potency is extraordinary. The evidence base, however, is unusually fragile for a compound attracting this level of interest. No human trial of dihexa itself has been conducted. The key mechanistic paper supporting its proposed pathway has since been retracted following a university finding of data falsification by researchers with direct financial interest in the compound’s commercialization, and the closely related injectable prodrug developed by the same parties failed in its pivotal dementia program. The most significant safety concern is the theoretical cancer risk from chronic activation of the hepatocyte growth factor pathway, one of the most extensively characterized cancer-promoting pathways in biology, compounded by an exceptionally long half-life that prevents rapid dose adjustment. All claims of cognitive enhancement in healthy individuals rest on extrapolation from rodent dementia models and uncontrolled anecdotal reports. For health-optimizing individuals, dihexa sits at an intersection of high speculative potential and high uncertainty, where the limited and partly compromised preclinical evidence must be weighed against irreducible unknowns about long-term human safety.

Top - Benefits - Risks - Protocol

Dihexa for Cognitive Enhancement

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Low 🟩

Procognitive Effects in Dementia Models

Synaptogenesis Promotion

Neuroprotective Effects

Speculative 🟨

Cognitive Enhancement in Healthy Individuals

Counteraction of Age-Related Synaptic Loss

Benefit-Modifying Factors

Potential Risks & Side Effects

Medium 🟥 🟥

Theoretical Cancer Risk via HGF/c-Met Pathway Activation ⚠️ Conflicted

Absence of Human Safety Data

Low 🟥

Overstimulation of Synaptogenesis

Reported Mild Side Effects (Anecdotal)

Peripheral HGF/c-Met Effects

Speculative 🟨

Long-Term Neurological Effects

Interaction with Undetected Pre-Cancerous Conditions

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion